Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Sniderman

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Current Opinion in Lipidology|May 29, 2009
Targets for LDL-lowering therapyAllan Sniderman
Journal of the American College of Cardiology|February 18, 2026
The PROACT Study and Improving Prevention of ASCVDAllan Sniderman
Journal of Clinical Lipidology|May 15, 2026
HDL and coronary artery diseaseMichael Pencina, Allan Sniderman
Clinical Chemistry|January 17, 2009
Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS)Allan Sniderman, Amirreza Solhpour
Current Opinion in Endocrinology, Diabetes, and Obesity|February 21, 2013
Update on the detection and treatment of atherogenic low-density lipoproteinsAllan Sniderman, Peter O Kwiterovich
The Journal of Pediatrics|November 12, 2013
Improving recognition of cardiovascular risk in childrenSamuel S Gidding, Allan Sniderman
Journal of Biomedical Research|August 16, 2017
Shunts, channels and lipoprotein endosomal traffic: a new model of cholesterol homeostasis in the hepatocyteRobert Scott Kiss, Allan Sniderman
Journal of Clinical Lipidology|January 28, 2026
Does apolipoprotein B matter in the care of familial hypercholesterolemia?Allan Sniderman, Gerald F Watts
Annals of Internal Medicine|February 17, 2010
ACP Journal Club. Either cholesterol or apolipoprotein levels can be used to determine risk for CVD; triglycerides are not usefulMatthew J McQueen, Allan Sniderman
Current Opinion in Lipidology|April 19, 2021
Update on apolipoprotein BAllan Sniderman, Michel Langlois, Christa Cobbaert
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Current Opinion in Lipidology|May 29, 2009
Targets for LDL-lowering therapyAllan Sniderman
Journal of the American College of Cardiology|February 18, 2026
The PROACT Study and Improving Prevention of ASCVDAllan Sniderman
Journal of Clinical Lipidology|May 15, 2026
HDL and coronary artery diseaseMichael Pencina, Allan Sniderman
Clinical Chemistry|January 17, 2009
Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS)Allan Sniderman, Amirreza Solhpour
Current Opinion in Endocrinology, Diabetes, and Obesity|February 21, 2013
Update on the detection and treatment of atherogenic low-density lipoproteinsAllan Sniderman, Peter O Kwiterovich
The Journal of Pediatrics|November 12, 2013
Improving recognition of cardiovascular risk in childrenSamuel S Gidding, Allan Sniderman
Journal of Biomedical Research|August 16, 2017
Shunts, channels and lipoprotein endosomal traffic: a new model of cholesterol homeostasis in the hepatocyteRobert Scott Kiss, Allan Sniderman
Journal of Clinical Lipidology|January 28, 2026
Does apolipoprotein B matter in the care of familial hypercholesterolemia?Allan Sniderman, Gerald F Watts
Annals of Internal Medicine|February 17, 2010
ACP Journal Club. Either cholesterol or apolipoprotein levels can be used to determine risk for CVD; triglycerides are not usefulMatthew J McQueen, Allan Sniderman
Current Opinion in Lipidology|April 19, 2021
Update on apolipoprotein BAllan Sniderman, Michel Langlois, Christa Cobbaert
Pageof 6